Jpmorgan Chase & CO Exelixis, Inc. Transaction History
Jpmorgan Chase & CO
- $1.14 Trillion
- Q2 2024
A detailed history of Jpmorgan Chase & CO transactions in Exelixis, Inc. stock. As of the latest transaction made, Jpmorgan Chase & CO holds 5,048,856 shares of EXEL stock, worth $173 Million. This represents 0.01% of its overall portfolio holdings.
Number of Shares
5,048,856
Previous 5,323,859
5.17%
Holding current value
$173 Million
Previous $126 Million
10.2%
% of portfolio
0.01%
Previous 0.01%
Shares
13 transactions
Others Institutions Holding EXEL
# of Institutions
468Shares Held
240MCall Options Held
2.04MPut Options Held
1.29M-
Black Rock Inc. New York, NY33.5MShares$1.15 Billion0.02% of portfolio
-
Vanguard Group Inc Valley Forge, PA29.7MShares$1.02 Billion0.01% of portfolio
-
Farallon Capital Management LLC San Francisco, CA27.1MShares$929 Million2.95% of portfolio
-
Jim Simons Renaissance Technologies LLC | New York, Ny15.2MShares$520 Million0.6% of portfolio
-
State Street Corp Boston, MA12.6MShares$432 Million0.01% of portfolio
About EXELIXIS, INC.
- Ticker EXEL
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 321,832,000
- Market Cap $11B
- Description
- Exelixis, Inc., an oncology-focused biotechnology company, focuses on the discovery, development, and commercialization of new medicines to treat cancers in the United States. The company's products include CABOMETYX tablets for the treatment of patients with advanced renal cell carcinoma who received prior anti-angiogenic therapy; and COMETRIQ ...